Which cervical and endometrial cancer patients will benefit most from intensity-modulated proton therapy?

Mariska A E van de Sande; Carien L Creutzberg; Steven van de Water; Abdul Wahab Sharfo; Mischa S Hoogeman

doi:10.1016/j.radonc.2016.06.016

Which cervical and endometrial cancer patients will benefit most from intensity-modulated proton therapy?

Radiother Oncol. 2016 Sep;120(3):397-403. doi: 10.1016/j.radonc.2016.06.016. Epub 2016 Jul 21.

Authors

Mariska A E van de Sande¹, Carien L Creutzberg², Steven van de Water³, Abdul Wahab Sharfo³, Mischa S Hoogeman³

Affiliations

¹ Department of Radiation Oncology, Leiden University Medical Center, The Netherlands.
² Department of Radiation Oncology, Leiden University Medical Center, The Netherlands. Electronic address: C.L.Creutzberg@lumc.nl.
³ Department of Radiation Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

PMID: 27452411
DOI: 10.1016/j.radonc.2016.06.016

Abstract

In this dosimetric comparison study it was shown that IMPT with robust planning reduces dose to surrounding organs in cervical and endometrial cancer treatment compared with IMRT. Especially for the para-aortic region, clinically relevant dose reductions were obtained for kidneys, spinal cord and bowel, justifying the use of proton therapy for this indication.

Keywords: Cervical cancer; Endometrial cancer; IMPT; IMRT; Treatment technique comparison.

MeSH terms

Endometrial Neoplasms / radiotherapy*
Female
Humans
Proton Therapy / methods*
Radiotherapy Dosage
Radiotherapy Planning, Computer-Assisted
Radiotherapy, Intensity-Modulated / methods*
Treatment Outcome
Uterine Cervical Neoplasms / radiotherapy*